Note: This document contains side effect information about carboprost. Some of the dosage forms listed on this page may not apply to the brand name Hemabate.
Applies to carboprost: intramuscular solution
Intramuscular route (Solution)
Carboprost tromethamine should be used only with strict adherence to recommended dosages like other potent oxytocic agents. Carboprost tromethamine should be used by medically trained personnel in a hospital which can provide immediate intensive care and acute surgical facilities.
Along with its needed effects, carboprost (the active ingredient contained in Hemabate) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking carboprost:
Less common or rare
Check with your doctor as soon as possible if any of the following side effects occur while taking carboprost:
Some side effects of carboprost may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Less common or rare
This procedure may result in some effects, which occur after the procedure is completed, that need medical attention. Check with your doctor if you notice any of the following:
Applies to carboprost: injectable solution
-Contractile effect on smooth muscle, nausea, vomiting, diarrhea, increased temperature and flushing are the most frequent adverse reactions observed.
-Adverse effects of this drug are generally transient and reversible when therapy ends.
-Endometritis, retained placental fragments, and excessive uterine bleeding were the most common complications after discharge from the hospital.
Transient pyrexia may be due to the effect of carboprost on hypothalamic thermoregulation. Temperature elevation exceeding 2 degrees Fahrenheit have been reported in approximately 12.5% of the patients who received the recommended dosage regimen. In all cases, temperature returned to normal when therapy ended.
Very common (10% or more): Vomiting and diarrhea (66%), nausea (33%)
Uncommon (0.1% to 1%): Hematemesis, upper abdominal pain, dry mouth
Frequency not reported: Epigastric pain, excessive thirst, taste alterations, gagging
Postmarketing reports: Retching
Pretreatment or concurrent administration of antiemetic and antidiarrheal drugs considerably decreases the very high incidence of gastrointestinal side effects that are common with all prostaglandins used for abortion.
Very common (10% or more): Body temperature increased (12%)
Uncommon (0.1% to 1%): Vertigo, tinnitus
Frequency not reported: Retained placental fragment
Postmarketing reports: Chest pain, asthenia
The degree of hypertension was moderate and it is not certain as to whether it was due to a direct effect of carboprost (the active ingredient contained in Hemabate) or a return to a status of pregnancy associated hypertension manifested by the correction of hypovolemic shock.
Common (1% to 10%): Flushing, hot flushing, chills
Uncommon (0.1% to 1%): Septic shock, tachycardia
Frequency not reported: Hypertension, shivering
Postmarketing reports: Palpitations
When carboprost (the active ingredient contained in Hemabate) was used for abortion, the most common complications which required additional treatment after discharge from the hospital were endometritis, retained placental fragments, and excessive uterine bleeding which was reported to have occurred in approximately 2% of patients.
Common (1% to 10%): Endometritis, uterine hemorrhage, retained placenta or membranes
Uncommon (0.1% to 1%): Urinary tract infection, uterine rupture, uterine cervical laceration, pelvic pain
Frequency not reported: Dysmenorrhea-like pain, uterine disorder, perforated uterus, uterine sacculation, uterine rupture
Common (1% to 10%): Headaches
Uncommon (0.1% to 1%): Syncope vasovagal, dizziness, dystonia, paresthesia, somnolence, dysgeusia, lethargy
Frequency not reported: Drowsiness, faintness, lightheadedness
Postmarketing reports: Nervousness, syncope
Common (1% to 10%): Cough
Uncommon (0.1% to 1%): Asthma, respiratory distress, dyspnea, hyperventilation, wheezing, hiccups
Frequency not reported: Nosebleed, bronchospasm, pharyngeal edema, upper respiratory tract infection, pulmonary edema, shortness of breath, fullness of throat
Postmarketing reports: Chocking sensation, epistaxis, dry throat
Uncommon (0.1% to 1%): Hyperhidrosis
Frequency not reported: Diaphoresis
Postmarketing reports: Rash
Uncommon (0.1% to 1%): Injection side pain
Uncommon (0.1% to 1%): Torticollis, back pain, myalgia
Frequency not reported: Breast tenderness, muscular pain, muscle spasms, leg cramps
Postmarketing reports: Blepharospasm
Uncommon (0.1% to 1%): Blurred vision, eye pain
Frequency not reported: Twitching eyelids
Uncommon (0.1% to 1%): Sleep disorders
Postmarketing reports: Anxiety
Frequency not reported: Thyroid storm
Postmarketing reports: Thyrotoxic crisis
Postmarketing reports: Anaphylactic reactions, anaphylactic shock, anaphylactoid reaction, angioedema
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Hemabate